|
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses. |
|
|
Consulting or Advisory Role - Agendia; Bayer; Lilly; Merck; Novartis; Peregrine Pharmaceuticals; Roche |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Honoraria - Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Speakers' Bureau - Novartis; Pfizer; Roche; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Esiai; Novartis; Pfizer |
Speakers' Bureau - Prime Oncology |
Travel, Accommodations, Expenses - Pierre Fabre |
|
|
Consulting or Advisory Role - Amgen; Novartis |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Consulting or Advisory Role - Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Eisai |
|
|
|
Consulting or Advisory Role - G1 Therapeutics |
Speakers' Bureau - Bristol-Myers Squibb; Genentech |
Research Funding - Bristol-Myers Squibb; Cascadian Therapeutics; G1 Therapeutics; Genentech; Novartis |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Novartis; Novartis (Inst) |
Speakers' Bureau - Novartis |
Research Funding - Novartis; Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Novartis (Inst) |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Merck; Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Genomic Health |